Skip to content
DraconiticResearch
Search Sources API
194,164 studies31 sourcesUpdated 25 min ago
Peer-reviewedCC BYPLOS One

Repurposing the phospholipase A2 inhibitor, darapladib, to combat multidrug-resistant fungal pathogens, including Candida auris

  • Yehia Elgammal1,2
  • Ehab A Salama1,2
  • Nour M Alkashef1,2
  • Christopher B Lawrence1,2
  • Mohamed N Seleem1,2
  1. 1Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
  2. 2Center for One Health Research, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.
Read full textPDFDOICite

Abstract

Candida auris is an emerging multidrug-resistant fungal pathogen and a major global health threat, highlighting the urgent need for new therapeutics. We screened ~2,600 FDA-approved drugs and clinical compounds and identified darapladib (DAL), a phospholipase A2 inhibitor, as a potent antifungal agent against multidrug-resistant C. auris. DAL exhibited antifungal activity against all tested C. auris isolates and showed broad-spectrum activity against other tested clinically important fungal pathogens, including other Candida, Cryptococcus, and mucormycosis-associated species, with minimum inhibitory concentrations of 4–16 μg/mL. DAL also displayed rapid fungicidal activity against C. auris and synergized with amphotericin B against C. auris and filamentous fungal pathogens. More importantly, serial exposure of C. auris to subinhibitory concentrations of DAL for 16 passages did not result in detectable resistance. Mechanistic studies indicated that DAL acts through an ergosterol-dependent membrane targeting mechanism, as exogenous ergosterol attenuated its activity and ergosterol-related haploinsufficient mutants showed reduced susceptibility. Consistent with this mechanism, DAL increased membrane permeability, nucleic acid leakage, and reactive oxygen species. In a Caenorhabditis elegans–C. auris infection model, DAL reduced the C. auris burden to below the limit of detection. Together, these findings support further investigation of DAL as a repurposed antifungal candidate against drug-resistant fungal infections.

Related

  1. Repurposing amlodipine, fluoxetine, and escitalopram as non-antibiotic adjuvants: in vitro enhancement of ciprofloxacin and fluconazole activity against multidrug-resistant bacterial and candida clinical isolates.
    Mohammed A Alkhawlani, Wafa M Al-Madhagi, Mahmoud Mahyoob Alburyhi +2
    BMC microbiologyPeer-reviewedCC BYFull textMicrobiologyEurope PMCDOAJ
  2. A virulent and temperate phage cocktail synergizes with antibiotics against multidrug-resistant Pseudomonas aeruginosa
    Jean Pierre González-Gómez, Elizabeth Deborah Elizalde-Flores, Cecille Bernardette Aispuro-Leal +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textEcologyCrossref
  3. Flavonoids from Pteris vittata L. Enhance Antibiotic Sensitivity to Multidrug‐Resistant Stenotrophomonas maltophilia
    Nhung‐phuong Nguyen, Vy‐yen Dao, Phuong‐khanh Dang +7
    ChemistrySelectPeer-reviewedHAL deposit licenceFull textGeneral biologyHAL
  4. Emergence of Genotype 2.3.1 Multidrug-Resistant Salmonella enterica Serovar Typhi Strain, West Africa, 2021–2025
    Elisabeth Njamkepo, Maria Pardos de la Gandara, Carolina Silva Nodari +2
    Emerging Infectious DiseasesPeer-reviewedCC BY 4.0Full textGeneral biologyHAL
  5. Strategies to prevent cross-transmission of multidrug-resistant microorganisms in intensive care units: A narrative review
    Gamze Kalin Unuvar, Emine Alp Mese, Jordi Rello
    Journal of Intensive MedicinePeer-reviewedCC BY-NC-ND 4.0Full text2 citedGeneral biologyEpidemiology & public healthHAL

Cite

BibTeXRIS
BibTeX
@article{elgammal2026repurposing,
  title = {{Repurposing the phospholipase A2 inhibitor, darapladib, to combat multidrug-resistant fungal pathogens, including Candida auris}},
  author = {Yehia Elgammal and Ehab A Salama and Nour M Alkashef and Christopher B Lawrence and Mohamed N Seleem},
  journal = {PLOS One},
  year = {2026},
  month = oct,
  doi = {10.1371/journal.pone.0361366},
  url = {https://doi.org/10.1371/journal.pone.0361366},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Repurposing the phospholipase A2 inhibitor, darapladib, to combat multidrug-resistant fungal pathogens, including Candida auris
AU  - Yehia Elgammal
AU  - Ehab A Salama
AU  - Nour M Alkashef
AU  - Christopher B Lawrence
AU  - Mohamed N Seleem
PY  - 2026
DA  - 2026/10/26
JO  - PLOS One
DO  - 10.1371/journal.pone.0361366
UR  - https://doi.org/10.1371/journal.pone.0361366
AB  - Candida auris is an emerging multidrug-resistant fungal pathogen and a major global health threat, highlighting the urgent need for new therapeutics. We screened ~2,600 FDA-approved drugs and clinical compounds and identified darapladib (DAL), a phospholipase A2 inhibitor, as a potent antifungal agent against multidrug-resistant C. auris. DAL exhibited antifungal activity against all tested C. auris isolates and showed broad-spectrum activity against other tested clinically important fungal pathogens, including other Candida, Cryptococcus, and mucormycosis-associated species, with minimum inhibitory concentrations of 4–16 μg/mL. DAL also displayed rapid fungicidal activity against C. auris and synergized with amphotericin B against C. auris and filamentous fungal pathogens. More importantly, serial exposure of C. auris to subinhibitory concentrations of DAL for 16 passages did not result in detectable resistance. Mechanistic studies indicated that DAL acts through an ergosterol-dependent membrane targeting mechanism, as exogenous ergosterol attenuated its activity and ergosterol-related haploinsufficient mutants showed reduced susceptibility. Consistent with this mechanism, DAL increased membrane permeability, nucleic acid leakage, and reactive oxygen species. In a Caenorhabditis elegans–C. auris infection model, DAL reduced the C. auris burden to below the limit of detection. Together, these findings support further investigation of DAL as a repurposed antifungal candidate against drug-resistant fungal infections.
SN  - 1932-6203
ER  -